Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02233855 · ClinicalTrials.gov registry record

People Presenting With Neurocysticercosis in North America

A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Terminated
Registry status
11
Enrollment target

NCT02233855 is a clinical trial that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 11 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02233855 was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

TERMINATED
Registry status
11 participants
Enrollment target

Study Summary

Background: \- Neurocysticercosis (NCC) is caused by tapeworms that infect people. NCC can lead to serious brain problems such as seizures, sevre headaches and difficulties with movements or sensation in the limbs. Researchers want to learn more about the different ways in which people in the United States present with this disease and how they respond to standard and newer treatments. Objective: \- To learn about the different forms of NCC that occurs throughout North America and how patients with these forms respond to treatment. Eligibility: \- Adults age 18 or older with NCC. Design: * Participants will be screened with: * Medical history and physical exam. * A computed tomography (CT) brain scan The participant will lie still on a table that slides into a large donut-shaped scanner. * Blood drawn through an arm vein for analysis * A magnetic resonance imaging (MRI) scan of the brain and spine. They will lay flat in a long metal cylinder as the machine makes images of the body. During the scan, participants will receive a contrast agent through an IV that allows high resolution imaging of the brain and spine * Participants will visit the clinic at 0, 1, 2, 3, 6, 12, and 24 months (7 times), and depending on the need for monitoring, more times. Participants will receive a schedule that will explain the procedures done at each visit. * At these visits, participants may: * Repeat the screening procedures. * Be asked about their NCC symptoms and their physical and mental health. * Have a urine test. * Take a test of their ability to concentrate, their memory and spatial recognition. * Have a lumbar puncture, if indicated by the state and severity of infection. A needle will be inserted through the skin and into the space between the bones in the back. Cerebrospinal fluid will be removed.

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2014-09-03
Est. Completion 2017-06-13

What the Registry Record Tells You About NCT02233855

The ClinicalTrials.gov registry entry for NCT02233855 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02233855 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02233855 about?

NCT02233855 is a clinical study titled "People Presenting With Neurocysticercosis in North America". Background: \- Neurocysticercosis (NCC) is caused by tapeworms that infect people. NCC can lead to serious brain problems such as seizures, sevre headaches and difficulties with movements or sensation in the limbs. Researchers want to learn more about the different ways in which people in the Unite...

What is the current status of trial NCT02233855?

This trial is currently terminated. The enrollment target is 11 participants. The study started on 2014-09-03. Estimated completion is 2017-06-13.

Who is sponsoring clinical trial NCT02233855?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.